These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 22118371)
1. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Söderlin MK; Petersson IF; Geborek P Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371 [TBL] [Abstract][Full Text] [Related]
2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related]
4. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648 [TBL] [Abstract][Full Text] [Related]
5. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338 [TBL] [Abstract][Full Text] [Related]
6. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Karlsson JA; Kristensen LE; Kapetanovic MC; Gülfe A; Saxne T; Geborek P Rheumatology (Oxford); 2008 Apr; 47(4):507-13. PubMed ID: 18304941 [TBL] [Abstract][Full Text] [Related]
7. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C; Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098 [TBL] [Abstract][Full Text] [Related]
8. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027 [TBL] [Abstract][Full Text] [Related]
9. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA. Söderlin MK; Petersson IF; Bergman S; Svensson B; Scand J Rheumatol; 2011; 40(4):249-55. PubMed ID: 21338325 [TBL] [Abstract][Full Text] [Related]
10. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315 [TBL] [Abstract][Full Text] [Related]
11. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. Mattey DL; Brownfield A; Dawes PT J Rheumatol; 2009 Jun; 36(6):1180-7. PubMed ID: 19447930 [TBL] [Abstract][Full Text] [Related]
13. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study. Arkema EV; Neovius M; Joelsson JK; Simard JF; van Vollenhoven RF Ann Rheum Dis; 2012 Jul; 71(7):1203-6. PubMed ID: 22504565 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Kristensen LE; Gülfe A; Saxne T; Geborek P Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547 [TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040 [TBL] [Abstract][Full Text] [Related]
17. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M; Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405 [TBL] [Abstract][Full Text] [Related]
18. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR; Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]